CN107709353A - 治疗癌症的方法和组合物 - Google Patents

治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN107709353A
CN107709353A CN201580074883.3A CN201580074883A CN107709353A CN 107709353 A CN107709353 A CN 107709353A CN 201580074883 A CN201580074883 A CN 201580074883A CN 107709353 A CN107709353 A CN 107709353A
Authority
CN
China
Prior art keywords
leu
seq
gly
ala
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580074883.3A
Other languages
English (en)
Chinese (zh)
Inventor
沙德哈克·森古普塔
普拉卡什·桑帕斯
理查德·P·容汉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plath Spector Chet Kell Rwmc LLC
Original Assignee
Plath Spector Chet Kell Rwmc LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plath Spector Chet Kell Rwmc LLC filed Critical Plath Spector Chet Kell Rwmc LLC
Publication of CN107709353A publication Critical patent/CN107709353A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
CN201580074883.3A 2014-12-02 2015-12-01 治疗癌症的方法和组合物 Pending CN107709353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
US62/086,346 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (1)

Publication Number Publication Date
CN107709353A true CN107709353A (zh) 2018-02-16

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580074883.3A Pending CN107709353A (zh) 2014-12-02 2015-12-01 治疗癌症的方法和组合物

Country Status (18)

Country Link
US (2) US9650428B2 (enExample)
EP (1) EP3227317A4 (enExample)
JP (1) JP2017537622A (enExample)
KR (1) KR20180041087A (enExample)
CN (1) CN107709353A (enExample)
AR (1) AR102879A1 (enExample)
AU (1) AU2015355084A1 (enExample)
BR (1) BR112017011771A2 (enExample)
CA (1) CA2969714A1 (enExample)
EA (1) EA201791210A1 (enExample)
HK (1) HK1251862A1 (enExample)
IL (1) IL252610A0 (enExample)
MX (1) MX2017007272A (enExample)
PH (1) PH12017501031A1 (enExample)
SG (2) SG11201704519YA (enExample)
TW (1) TW201636425A (enExample)
UY (1) UY36418A (enExample)
WO (1) WO2016089916A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN113304267A (zh) * 2021-06-11 2021-08-27 河南大学 肺癌的治疗靶点及其应用
CN114014941A (zh) * 2022-01-10 2022-02-08 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115551882A (zh) * 2020-01-31 2022-12-30 希望之城公司 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN110615835A (zh) 2012-08-09 2019-12-27 利兰斯坦福初级大学董事会 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer
CA2989949A1 (en) * 2015-06-19 2016-12-22 Sebastian KOBOLD Pd-1-cd28 fusion proteins and their use in medicine
AU2016301932B2 (en) * 2015-08-05 2020-02-27 CellabMED Inc. Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2018112266A1 (en) * 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
JP2021503303A (ja) * 2017-11-20 2021-02-12 プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃａｒ−ｔ細胞の機能性を改善するための組成物およびその使用
EP3728305A1 (en) 2017-12-20 2020-10-28 Poseida Therapeutics, Inc. Vcar compositions and methods for use
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
TW202210632A (zh) * 2020-05-28 2022-03-16 日商中外製藥股份有限公司 經改良之顆粒酶b變體
EP4204443A4 (en) * 2020-08-26 2025-02-26 The Regents of The University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLIOBLASTOMA
WO2022056398A1 (en) * 2020-09-11 2022-03-17 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for prevention and treatment of influenza infections
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1411512A (zh) * 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 嵌合的免疫原性组合物及其编码核酸
CN101355934A (zh) * 2005-11-16 2009-01-28 墨西哥国立自治大学 转录组修饰剂和化学疗法或放射疗法对抗癌症的应用
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
US20120148552A1 (en) * 2008-08-26 2012-06-14 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003073841A2 (en) * 2002-03-01 2003-09-12 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PL2552959T3 (pl) * 2010-03-26 2017-08-31 Memorial Sloan-Kettering Cancer Center Przeciwciała przeciwko MUC16 i metody stosowania
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
KR102332790B1 (ko) * 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
ES2792849T3 (es) * 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1411512A (zh) * 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 嵌合的免疫原性组合物及其编码核酸
CN101355934A (zh) * 2005-11-16 2009-01-28 墨西哥国立自治大学 转录组修饰剂和化学疗法或放射疗法对抗癌症的应用
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
US20120148552A1 (en) * 2008-08-26 2012-06-14 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KREBS,S 等: "T CELLS REDIRECTED TO IL13Rα2 WITH IL13 MUTEIN-CARS HAVE ANTIGLIOMA ACTIVITY BUTALSO RECOGNIZE IL13Rα1", 《CYTOTHERAPY》 *
LA WRENCE S. LAM B JR 等: "Engin eered Drug Res istant cd T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy", 《PLOS ONE》 *
SEOGKYOUNG KONG 等: "Suppression of Human Glioma Xenografts with 2nd Generation IL13R-Specific Chimeric Antigen receptor-Modified T Cells", 《CLINICAL CANCER RESEARCH》 *
SIMONE KREBS 等: "Genetically modified T cells to target glioblastoma", 《FRONT ONCO.》 *
ZHANG,JG等: "IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A SOLUBLE INTERLEUKIN(IL)-13-BINDING PROTEIN", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 *
刘宏雷: "MGMT在替莫唑胺（TMZ）治疗恶性脑胶质瘤中的表达及意义", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
CN115551882A (zh) * 2020-01-31 2022-12-30 希望之城公司 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞
CN113304267A (zh) * 2021-06-11 2021-08-27 河南大学 肺癌的治疗靶点及其应用
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941A (zh) * 2022-01-10 2022-02-08 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途

Also Published As

Publication number Publication date
BR112017011771A2 (pt) 2018-07-10
PH12017501031A1 (en) 2017-11-27
CA2969714A1 (en) 2016-06-09
SG11201704519YA (en) 2017-07-28
EP3227317A1 (en) 2017-10-11
EA201791210A1 (ru) 2017-11-30
MX2017007272A (es) 2018-06-06
IL252610A0 (en) 2017-07-31
US9650428B2 (en) 2017-05-16
HK1251862A1 (zh) 2019-04-26
KR20180041087A (ko) 2018-04-23
SG10202103475XA (en) 2021-05-28
US20160151490A1 (en) 2016-06-02
EP3227317A4 (en) 2018-04-25
AR102879A1 (es) 2017-03-29
AU2015355084A1 (en) 2017-06-29
US20180072789A1 (en) 2018-03-15
JP2017537622A (ja) 2017-12-21
WO2016089916A1 (en) 2016-06-09
TW201636425A (zh) 2016-10-16
UY36418A (es) 2016-06-30

Similar Documents

Publication Publication Date Title
US9650428B2 (en) Methods and compositions for treating cancer
JP7082046B2 (ja) 受容体
KR20210019993A (ko) Τ 세포 수용체 및 이를 발현하는 조작된 세포
WO2018193231A1 (en) Cell
CN111479918A (zh) 细胞
CN114514247B (zh) Car-cd123载体及其用途
US20230348560A1 (en) Chimeric ilt receptor compositions and methods
HK1243107A1 (en) Chimeric protein
HK1243107B (en) Chimeric protein
KR20230008153A (ko) 세포
JP7591772B2 (ja) 強化された合成ｔ細胞受容体及び抗原受容体
JP6842688B2 (ja) キメラ抗原受容体
US20250108069A1 (en) Chimeric adaptor polypeptides
JP7054181B2 (ja) キメラ抗原受容体
CN117683136A (zh) 嵌合抗原受体、慢病毒、修饰nk细胞及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251862

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180216

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1251862

Country of ref document: HK